10-K: Revium Rx Faces Going Concern Doubt Amidst R&D Losses

Revium Rx, a preclinical biopharmaceutical company, reported a significant net loss of $13.4 million in 2025 and faces substantial doubt about its ability to continue as a going concern, compounded by a dispute over its Nano-Candesartan license.

Summary

• Revium Rx is a preclinical stage biopharmaceutical company focused on developing innovative nanoparticle-based therapies for antimicrobial resistance, solid tumors, and vaccination.
• The company reported a net loss of $13.449 million for the year ended December 31, 2025, a 283.7% increase compared to the combined 2024 loss of $3.505 million.
• Operating loss for 2025 totaled $13.148 million, representing a 268.5% increase from the combined 2024 loss of $3.568 million.
• Intangible asset and goodwill impairment expenses amounted to $9.684 million in 2025, primarily due to a dispute regarding the Nano-Candesartan program.
• Cash and short-term deposits decreased from $5.279 million as of December 31, 2024, to $2.711 million as of December 31, 2025.
• The accumulated deficit reached $24.962 million as of December 31, 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern without securing additional investments.
• Nano-Mupirocin, a lead product candidate for antibiotic-resistant infections (MRSA, VRE, resistant Neisseria gonorrhoeae), is in early-stage development, with manufacturing scaled up to a 25-liter clinical batch and GLP toxicology studies ongoing (expected completion May 2026).
• The company received approval from the Israeli Ministry of Health to initiate a Phase 1 clinical trial for Nano-Mupirocin in Israel.
• Nano-Candesartan, a second product candidate for enhancing cancer treatments (initially pancreatic cancer), is subject to an ongoing dispute with Yissum regarding the option to obtain an exclusive license, which has led to the impairment of associated intangible assets.
• Liposomal Protein-Loaded Technology (LPLT) for novel vaccines (SARS-CoV-2, West Nile Virus) is in early-stage development, with a SARS-CoV-2 challenge study expected to conclude in Q2 2026, delayed from Q3 2025 due to BSL-3 unit contamination.
• The U.S. patent for the LPLT delivery system (CCS) is scheduled to expire in February 2027.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report due to the significant increase in net loss, substantial impairment charges, and explicit "going concern" doubt. While preclinical data shows promise, the financial instability and key license dispute create considerable uncertainty for future development and commercialization.

Positives

• The company is developing proprietary nanoparticle-based therapies targeting high unmet medical needs in antimicrobial resistance, solid tumors, and vaccination.
• Nano-Mupirocin demonstrated superior therapeutic efficacy in multiple preclinical animal models for severe antibiotic-resistant infections, including S. aureus bloodstream infection, neutropenic lung infection, MRSA endocarditis, and necrotizing fasciitis.
• Preclinical pharmacokinetic studies showed Nano-Mupirocin achieved a 97-fold higher area under the curve (AUC) and an extended terminal half-life of 262 minutes compared to 5.3 minutes for the free drug.
• Nano-Mupirocin exhibits broad antibacterial activity against high-priority pathogens like MRSA, VRE, and resistant Neisseria gonorrhoeae, with no observed cross-resistance to other antibiotics.
• The manufacturing process for Nano-Mupirocin has been successfully scaled up to a 25-liter clinical batch, and all excipients used are pharmaceutical grade and approved for human use.
• Received regulatory approval from the Israeli Ministry of Health to initiate a Phase 1 clinical trial for Nano-Mupirocin in Israel.
• Nano-Mupirocin may be eligible for Qualified Infectious Disease Product (QIDP) and Fast Track designations, potentially offering priority review and extended market exclusivity.
• The company is assessing potential indications for Nano-Mupirocin that may qualify for Orphan Drug Designation (ODD), which could provide market exclusivity, FDA fee waivers, and tax credits.
• Preclinical studies for Nano-Candesartan suggest its potential to improve cancer treatment outcomes by modulating the tumor microenvironment and reducing systemic side effects like hypotension when used in combination with existing therapies.
• The Liposomal Protein-Loaded Technology (LPLT) platform is being designed to offer more durable, broader cross-immunity for vaccines with potentially minimal side effects.
• The company holds exclusive worldwide licenses for the development and commercialization of Nano-Mupirocin and LPLT from Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
• Several patents for Nano-Mupirocin have been obtained in major countries and regions (U.S., Europe, Japan, India, China), with expiry dates extending to April 8, 2035.

Negatives

• The company has a history of losses and expects to continue incurring operating losses and negative cash flow for the foreseeable future, with an accumulated deficit of $24.962 million as of December 31, 2025.
• Net loss for the year ended December 31, 2025, significantly increased to $13.449 million, up 283.7% from the combined 2024 loss of $3.505 million.
• Operating loss for 2025 increased to $13.148 million, a 268.5% rise from the combined 2024 loss of $3.568 million.
• The company incurred substantial intangible asset and goodwill impairment expenses of $9.684 million in 2025, primarily due to the dispute over the Nano-Candesartan program.
• Cash and short-term deposits decreased by approximately 48.6% from $5.279 million in 2024 to $2.711 million in 2025.
• There is substantial doubt about the company's ability to continue as a going concern without securing additional financing, for which there are currently no binding commitments.
• An ongoing dispute with Yissum regarding the option to obtain an exclusive license for the Nano-Candesartan program could lead to its exclusion from the development pipeline and has already resulted in asset impairment.
• The SARS-CoV-2 challenge study for the LPLT platform was delayed due to contamination of the specialized BSL-3 unit.
• The U.S. patent for the LPLT delivery system (CCS) is set to expire in February 2027, posing a risk to the protection of the original lipid-based vaccine delivery technology.
• All product candidates are in early preclinical stages and have not yet been clinically tested in humans in the United States or elsewhere, with no guarantee of efficacy or safety in human populations.
• The company's disclosure controls and procedures were deemed not effective as of December 31, 2025.
• The Chief Financial Officer, Arie Gordashnikov, has competing demands on his time and attention, as he serves in the same capacity for other companies.
• The company's Common Stock is considered a penny stock, which is subject to restrictions on marketability and potential significant price fluctuations.
• The Board of Directors has not established any committees, meaning the entire Board participates in nomination, audit oversight, and compensation processes, which could lead to potential conflicts of interest.

Risks

• The availability and adequacy of capital to support and grow the business is uncertain.
• Economic, competitive, business, and other conditions in local and regional markets may adversely affect operations.
• Actions taken or not taken by competitors, legislative, regulatory, judicial, and other governmental authorities pose risks.
• Intense competition exists in the biopharmaceutical industry.
• Changes in business and growth strategy, capital improvements, or development plans could impact the company.
• Additional capital may not be available to support research and development, and clinical trials.
• Inability to raise additional funds when needed could force delays, reductions, or elimination of product development programs or commercialization efforts, potentially leading to business failure.
• There is substantial doubt about the company's ability to continue as a going concern.
• Failure to comply with contractual obligations under the Yissum License Agreements could result in the loss of necessary license rights.
• Uncertainty surrounding the option to obtain an exclusive license to the Nano-Candesartan program, including a disagreement with Yissum, could limit the development pipeline and adversely affect the business.
• The Chief Financial Officer may face competing demands on his time and attention, potentially hindering the company's progress.
• Dependence on a relatively small group of officers and directors, and their potential conflicts of interest in allocating time, could adversely affect operations.
• Conducting clinical trials involves inherent risks, including recruitment challenges, safety concerns, and demonstrating efficacy.
• There is always a risk of adverse reactions or unexpected safety issues emerging during clinical trials or after drug approval.
• Preclinical studies showing promising results do not guarantee sufficient efficacy or safety in human populations.
• Tumor heterogeneity and adaptive resistance within the tumor microenvironment may impact the effectiveness of Nano-Candesartan.
• Scaling up production of ARB-based therapies can be complex, costly, and subject to issues related to manufacturing consistency and quality control.
• Obtaining regulatory approval for drug-product candidates requires rigorous evaluation with no guarantee of success.
• Gaining market access and competing with established treatments pose significant challenges for new therapy candidates.
• High development costs and uncertainties regarding reimbursement for new therapies may impact commercial viability.
• Significant disruptions to information technology systems or breaches of information security, including cybersecurity and data leakage risks, could adversely affect the business.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable.
• Approval for a product candidate in one country does not ensure approval in any other jurisdiction.
• Additional time and costs may be required to obtain marketing authorizations for combination therapies like the ARB-based product candidate.
• Combination therapy carries risks of unexpected toxicity due to drug-drug interactions or overlapping adverse effects.
• Regulatory agencies may require demonstration of incremental benefit for combination therapies, necessitating larger, more complex, and costlier clinical trials.
• The market acceptance of a combination therapy depends on the availability, pricing, and reimbursement of the partner drug.
• Use of off-patent or competitor-owned drugs in combinations may complicate exclusivity, licensing, and long-term value capture.
• There is no assurance that expedited development or approval pathways will be granted or will accelerate clinical development or approval.
• LNP-based product candidates in combination with other therapies may result in unexpected adverse effects.
• Bacteria may develop resistance to the novel formulation of Nano-Mupirocin over time.
• The company may not be successful in establishing and maintaining development and commercialization collaborations.
• The success of business operations is dependent on the ability to successfully develop products and complete clinical programs, with no assurance of commercial success.
• Pending patent applications may not result in issued patents, or any granted patents could include only limited claims, weakening intellectual property protection.
• Any patents held may be challenged, circumvented, or invalidated by third parties.
• Inability to protect trademarks, patents, and trade secrets may prevent successful marketing and effective competition.
• The company may be charged with infringement of patented technology owned by others.
• Freedom to operate issues exist due to the competitive nature of the business and similar patent protection sought by others.
• Inability to secure new patent protection for the LPLT-based immunization platform approach, or only partial claim approvals, could limit IP scope.
• The U.S. patent relating to the proprietary lipid-based delivery system for LPLT is scheduled to expire in February 2027.
• The company may be subject to legal claims, including product liability or infringement claims, which could have a significant impact on financial performance.
• Operations in Israel may be adversely affected by political, economic, and military instability, including ongoing conflicts.
• Operations and those of contractors in Israel may be disrupted by the obligation of Israeli citizens to perform military service.
• Future sales may be adversely affected by boycotts of Israel.
• Limitations on transfers of technology developed with Israel Innovation Authority (IIA) grants exist.
• Principal stockholders can significantly influence or control matters requiring a shareholder vote.
• The sale of a large number of shares of Common Stock by principal stockholders could depress the market price.
• Common Stock is considered a penny stock, subject to restrictions on marketability and difficult to buy or sell.
• The market price of Common Stock may fluctuate significantly in the future.
• Securities class action litigation may be brought against the company following periods of stock price volatility.
• The requirements of becoming an SEC reporting public company may strain resources, divert management attention, and affect the ability to attract and retain executive management and qualified board members.
• Internal controls may be inadequate, causing financial reporting to be unreliable and leading to misinformation.
• The costs of being an SEC-reporting public company could result in the inability to continue as a going concern.
• An active, liquid trading market for Common Stock may not develop or be sustained.
• The trading market for Common Stock will be influenced by equity research analysts, and downgrades or cessation of coverage could cause share price decline.
• The company does not intend to pay dividends on its Common Stock.
• Nevada law and provisions in the Articles of Incorporation and bylaws could make a merger, tender offer, or proxy contest difficult, thereby depressing the market price of Common Stock.

Future Outlook

The company plans to advance its preclinical product candidates, Nano-Mupirocin, Nano-Candesartan, and the Liposomal Protein-Loaded Technology (LPLT) vaccine platform, through IND-enabling studies and clinical trials. Nano-Mupirocin Phase 1 trials are scheduled to commence in Q3 2026, with a pre-IND meeting with the U.S. FDA planned for Q4 2026 early 2027. Clinical trials for Nano-Candesartan are anticipated in H2 2027, contingent on resolving the ongoing dispute with Yissum regarding the license option. New patent applications for the LPLT platform are expected by Q2 2026 following the completion of challenge studies. The company intends to seek expedited regulatory pathways and strategic partnerships for funding and commercialization, while also expanding its IP strategy and generating high-impact publications.

Management Comments

• Our forward-looking statements reflect the good faith judgment of our management, these statements can be based only on facts and factors of which we are currently aware.
• We believe that our novel liposomal Nano-Mupirocin product candidate may potentially present significant advancement in antibiotic therapy by enabling systemic use of mupirocin.
• Management believes that the novel formulation of Nano-Mupirocin may hold the potential to serve as a highly potent systemic therapy for serious life-threatening infections, such as resistant Gonorrhea, MRSA induced endocarditis, or sepsis.
• Management expects that the Company will be able to proceed with submission of an IND application with the FDA and preparedness for clinical trials, subject to raising additional capital.
• Management believes that this comprehensive plan is designed to ensure that Nano-Mupirocin progresses systematically through manufacturing and clinical evaluation, adhering to regulatory standards and providing the necessary data to support further development.
• Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.
• Management anticipates that additional capital will be necessary to fund its ongoing R&D activities and to explore opportunities for acquiring healthcare or healthcare-related technologies.
• We believe our relationship with our employees is excellent in most cases.

Industry Context

StockSavvy.ai notes that Revium Rx operates in the highly competitive and rapidly evolving nanomedicine and biopharmaceutical sectors, targeting critical global health challenges like antimicrobial resistance (AMR) and solid tumors. The company leverages lipid nanoparticle (LNP) technology, building on the success of established nanomedicines like Doxil and mRNA vaccines (Pfizer-BioNTech, Moderna), which have demonstrated the potential for enhanced drug delivery and efficacy. The focus on repurposing existing drugs (mupirocin, candesartan) via novel delivery systems aligns with industry trends seeking to de-risk development and accelerate market entry for high-unmet-need indications. However, the significant R&D costs and regulatory hurdles are typical for preclinical biotechs, and the dispute over the Nano-Candesartan license highlights the complexities of intellectual property in this field.

Comparison to Industry Standards

• Nano-Mupirocin's estimated treatment course price of $315-$1,200 (illustrative base case $600) for resistant gonorrhea is benchmarked against Ceftriaxone ($538) and topical Mupirocin (~$45), reflecting a potential ~7x premium observed for liposomal Amphotericin B (AmBisome, ~$341 per 50 mg dose) compared to conventional Amphotericin B (~$51 per 50 mg dose).
• For invasive MRSA, Nano-Mupirocin's assumed IV pricing of ~$220 per dose, with a total course cost ranging from ~$1,540 to $3,000 (average ~$2,200), is benchmarked against liposomal Amphotericin B (~$120-$341 per dose, with a total course cost of ~$1,700-$4,700).
• The global anticancer therapeutics market, valued at approximately $222.71 billion in 2023, is projected to reach around $885.44 billion by 2033, reflecting a compound annual growth rate (CAGR) of 14.80%, indicating a robust market for Nano-Candesartan if successful.
• Pancreatic Ductal Adenocarcinoma (PDAC) has a 5-year survival rate under 11%, highlighting the significant unmet medical need that Nano-Candesartan aims to address, where current standard therapies like combination chemotherapy with Gemcitabine and Nab-Paclitaxel offer only limited survival benefits.
• The LPLT vaccine platform competes with established mRNA vaccines (e.g., Pfizer-BioNTech's Comirnaty, Moderna's Spikevax), viral vector vaccines (e.g., AstraZeneca-Oxford, Johnson & Johnson), and protein subunit vaccines (e.g., Novavax, Sanofi-GSK), each with distinct profiles in terms of efficacy, safety, storage requirements, and adaptability to new variants.

Management Changes

Corporate Governance

Legal Proceedings

• There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company.

Related Party Transactions

• On December 31, 2024, Inna Martin, the company's Chief Operating Officer, exercised 2,800,000 stock options into 2,800,000 common stock at an exercise price of $0.001 per share.
• On February 9, 2024, the Board approved a grant to David Akunis, the company's then Chief Executive Officer, of 3,800,000 stock options at an exercise price of $0.001 per share.
• On February 9, 2024, the Board approved a grant to Bernard Bartal, the Chairman of the Board, of 160,000 stock options at an exercise price of $0.40 per share.
• On February 9, 2024, the Board agreed to extend the exercise period of options for 690,000 shares previously granted in 2021 to Yoram Drucker, a director, and a service provider through September 30, 2031.
• Bernard Bartal received $35,800 in 2025 for his role as the company's VP head of strategy, in addition to his director fees.
• Yoram Drucker received $83,000 in 2025 for his salary from the company's subsidiary Lipovation Ltd., in addition to his director fees.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises and a high risk of losing their investment due to the company's "going concern" doubt and accumulated deficit.
• Shareholders may experience market price volatility and limited liquidity for the company's penny stock, further exacerbated by the dispute over the Nano-Candesartan license.
• Employees in Israel may experience disruptions to their work due to military service obligations, potentially impacting R&D timelines.
• Customers and patients could potentially benefit from novel therapies for life-threatening conditions (AMR, cancer, viral diseases) if the company's product candidates are successfully developed and commercialized.
• Creditors face a heightened risk of non-payment if the company fails to secure additional financing and is unable to continue as a going concern.
• Suppliers and partners, such as STA Pharmaceutical and Yissum, face risks of delayed or terminated contracts if the company encounters further financial difficulties or unresolved disputes.

Next Steps

• Complete final batch release for the 25-liter clinical batch of Nano-Mupirocin.
• Complete GLP toxicology studies for Nano-Mupirocin (expected May 2026).
• Initiate Phase 1 clinical trial for Nano-Mupirocin in Israel (scheduled Q3 2026).
• Conduct a pre-Investigational New Drug (pre-IND) meeting with the U.S. FDA for Nano-Mupirocin (planned Q4 2026 early 2027).
• Analyze Phase 1 data for Nano-Mupirocin to establish its pharmacokinetic profile and inform subsequent clinical development strategy.
• Resolve the dispute with Yissum regarding the Nano-Candesartan license option.
• Conduct a dose-dependent study to evaluate Nano-Candesartan's effect on blood pressure in large animals (planned H2 2026).
• Undertake IND-enabling preclinical studies for Nano-Candesartan (therapeutic efficacy testing, preliminary pharmacokinetics, tumor biodistribution).
• Develop and validate bioanalytical methods for Nano-Candesartan.
• Scale up the manufacturing process for Nano-Candesartan from lab scale to pilot scale.
• Perform long-term and accelerated stability tests for Nano-Candesartan.
• Submit an IND application with the FDA for Nano-Candesartan.
• Initiate clinical trials for Nano-Candesartan (anticipated H2 2027, if the option is exercised).
• Complete the SARS-CoV-2 challenge study for the LPLT platform (expected Q2 2026).
• Complete the West Nile Virus (WNV) evaluation for the LPLT platform.
• Draft and submit new provisional patent applications for LPLT, focusing on antigen-specific compositions (anticipated Q2 2026).
• Evaluate go/no-go decision for advancement of either the SARS-CoV-2 or WNV vaccine candidate (Q2 2026).
• Initiate IND-enabling GLP studies for the selected LPLT candidate (Q3 2026-Q3 2027).
• Develop clinical study protocol and prepare a standard IND submission for the chosen LPLT indication (Q3-Q4 2027).
• Initiate Phase 1 trial for LPLT (Q2 2028, pending IND clearance).
• Recruit an in-house development team.
• Seek funding through potential clinical collaboration agreements and non-dilutive grant programs.
• Further develop and strengthen its IP strategy and submit more patent applications, including for Orphan Drug Designation protection.
• Generate high-impact publications in collaboration with Key Opinion Leaders (KOLs) and leading researchers.
• Expand the development program for Nano-Mupirocin to include a wider range of indications.
• Develop a comprehensive target market strategy for Nano-Mupirocin, including key regions affected by antibiotic resistance.
• Cultivate long-term relationships and collaborations with key institutions, health organizations, NGOs, and governments.
• Initiate strategic collaborations with leading oncology-focused pharmaceutical companies for ARB combination therapy.
• Prioritize high-impact cancer indications for ARB where the tumor microenvironment significantly impacts treatment outcomes.
• Pursue early and continuous engagement with regulatory bodies for ARB development.
• Expand and protect the intellectual property landscape around the main ARB patent.
• Strategically release clinical trial results and other key data milestones for ARB.
• Evaluate exit opportunities for ARB following pivotal Phase 2 data.
• Broaden the scope of ARB development program to explore its potential across a diverse array of solid tumors.
• Engage with major pharmaceutical companies regarding existing cancer therapy products to integrate combination therapy nano-ARB.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating "substantial doubt about our ability to continue as a going concern" and reporting a significant increase in net loss and impairment charges. While it has promising preclinical programs, the high burn rate, dependence on uncertain future funding, and a critical dispute over a key license (Nano-Candesartan) create an extremely high-risk investment profile. The ineffective disclosure controls and penny stock status further exacerbate these concerns, making it a strong sell for seasoned investors.

Keywords

nanomedicine, biopharmaceutical, antimicrobial resistance, solid tumors, vaccination, Nano-Mupirocin, Nano-Candesartan, LPLT, liposomal drug delivery, preclinical, MRSA, VRE, Neisseria gonorrhoeae, pancreatic cancer, SARS-CoV-2, West Nile Virus, SEC filing, 10-K, going concern, Yissum, intellectual property, drug development, clinical trials, biotech, pharmaceuticals